| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Feb 2025 | 22 Jan 2025 |
| Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve Prior Intimation for the Board Meeting of the Company to be held on Tuesday 04th February 2025. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 04, 2025 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 31st December, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; 2.Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today has ratified incorporation of a Wholly Owned Subsidiary (WOS) with the name as Fredun Retail Private Limited as approved by the Ministry of Corporate Affairs, Government of India. (As Per Bse Announcement Dated on 04.02.2025) | ||
| Board Meeting | 26 Oct 2024 | 15 Oct 2024 |
| Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2024 inter alia to consider and approve 1. To discuss consider and approve Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2024. OUTCOME OF THE BOARD MEETING HELD ON SATURDAY 26TH OCTOBER, 2024 (As Per BSE Announcement Dated on: 26/10/2024) | ||
| Board Meeting | 3 Oct 2024 | 26 Sep 2024 |
| Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/10/2024 inter alia to consider and approve We wish to inform you that pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors (the Board) of Fredun Pharmaceuticals Limited (the Company) is scheduled to be held on Thursday 03rd October 2024 to inter alia consider issue and allotment of Unsecured Foreign Currency Convertible Bonds (FCCBs) in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 and any other regulations and rules as applicable as amended subject to such regulatory/ statutory approvals as may be required. Issue of FCCBs Issue of 100 (One Hundred) Unsecured Foreign Currency Convertible Bonds of an aggregate principal amount of USD 10,000,000 (Ten Million United States Dollars) at an Issue Price of USD 100,000 (One Hundred Thousand United States Dollars) each at zero coupon and an aggregate yield to maturity of 7% (Seven Per Cent.), with a maturity tenure of 10 (Ten) years and 1 (One) day due October 04, 2034, on private placement basis to Amicorp Capital (Mauritius) Limited. The Company, at its discretion, may issue a further 20 (Twenty) Unsecured Foreign Currency Convertible Bonds of an aggregate amount of USD 2,000,000 (Two Million United States Dollar) (Green Shoe Option) within 30 (thirty) days from the closing date. (As Per BSE Announcement dated on 03.10.2024) | ||
| Board Meeting | 29 Jul 2024 | 20 Jul 2024 |
| Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Notice is hereby given pursuant to Reg 29 read with Regulation 33 of SEBI (LODR) Reg 2015 that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Monday 29th July 2024 inter alia to consider and approve the following: 1. To discuss consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30 2024. 2. Any other matter with the permission of the Chair. Further in continuation of our intimation dated June 27 2024 and pursuant to Companys Code of Conduct formed under the SEBI (PIT ) Regulations 2015 and amendments thereunder the trading window for dealing in the securities of the Company has been closed from July 01 2024 and it shall remain closed until forty-eight hours after the date of declaration of results for the Quarter ended June 30 2024. The same has been circulated to the Directors Key Managerial Personnel Employees of the Company and their immediate relatives. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, July 29, 2024 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 30th June, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; In furtherance to the intimation filed by the Company dated June 27, 2024; the trading window for trading in securities of the Company by insiders closed on July 01, 2024 till the end of 48 hours after the declaration of outcome of Board Meeting. The Board Meeting commenced at 04:00 p.m. and concluded at 07:15 p.m Outcome of Board Meeting along with financial Results for the quarter ended 30th June, 2024 (As per BSE Announcement Dated on 29/07/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
